Objective: To evaluate the number of patients with early-stage breast cancer who could benefit from the omission of axillary surgery following the application of the Alliance for Clinical Trials in Oncology (ACOSOG) Z0011 trial criteria.
Methods: A retrospective cohort study conducted in the Hospital da Mulher da Universidade Estadual de Campinas. The study population included 384 women diagnosed with early-stage invasive breast cancer, clinically negative axilla, treated with breast-conserving surgery and sentinel lymph node biopsy, radiation therapy, chemotherapy and/or endocrine therapy, from January 2005 to December 2010. The ACOSOG Z0011 trial criteria were applied to this population and a statistical analysis was performed to make a comparison between populations.
Results: A total of 384 patients underwent breast-conserving surgery and sentinel lymph node biopsy. Of the total number of patients, 86 women underwent axillary lymph node dissection for metastatic sentinel lymph nodes (SNLs). One patient underwent axillary node dissection due to a suspicious SLN intraoperatively, thus, she was excluded from the study. Among these patients, 82/86 (95.3%) had one to two involved sentinel lymph nodes and met the criteria for the ACOSOG Z0011 trial with the omission of axillary lymph node dissection. Among the 82 eligible women, there were only 13 cases (15.9%) of lymphovascular invasion and 62 cases (75.6%) of tumors measuring up to 2 cm in diameter (T1).
Conclusion: The ACOSOG Z0011 trial criteria can be applied to a select group of SLN-positive patients, reducing the costs and morbidities of breast cancer surgery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183926 | PMC |
| http://dx.doi.org/10.1055/s-0041-1725052 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy.
Minerva Surg
October 2024
Breast Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Article Synopsis
- - Recent advancements in breast cancer treatment suggest replacing axillary lymph node dissection (ALND) with sentinel lymph node biopsy (SLNB) for patients with positive sentinel lymph nodes undergoing mastectomy, to reduce morbidity.
- - A review of various studies, including major trials like ACOSOG Z0011 and SINODAR-ONE, indicates that omitting ALND in mastectomy patients does not significantly affect recurrence-free survival (RFS) or overall survival (OS).
- - Ongoing trials, such as POSNOC, aim to further evaluate this approach, emphasizing the need for more randomized clinical trials to validate these findings and improve treatment protocols for breast cancer patients.
The prevalence of non-sentinel lymph node metastasis among breast cancer patients with sentinel lymph node involvement and its impact on clinical decision-making: a single-centred retrospective study.
Oncol Rev
October 2024
Department of Radiation Oncology, Affiliated Rehabilitation Hospital of Nanchang University, Nanchang, Jiangxi, China.
Article Synopsis
- Sentinel lymph node biopsy (SLNB) is standard for early breast cancer patients, revealing significant non-sentinel lymph node (non-SLN) metastasis rates, impacting treatment choices.
- A study of 892 female patients showed that 56.5% with positive sentinel lymph nodes had non-SLN metastasis, with rates increasing alongside the number of positive SLNs.
- Findings indicated that non-SLN metastasis is linked to various factors like tumor size and grade, suggesting that precise staging can guide more effective treatment strategies for breast cancer patients.
Should Palpable Nodes Be Exclusionary in Patients Who Are Otherwise Candidates for ACOSOG Z0011-Type Trials?
Ann Surg Oncol
October 2024
Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Background: Palpable nodes were exclusionary in American College of Surgeons Oncology Group (ACOSOG) Z0011, while SINODAR-ONE excluded those with positive axillary nodes by palpation and ultrasound. To determine whether clinical nodal status should be exclusionary in those fulfilling pathologic criteria for ACOSOG Z0011 and similar trials, this study analyzed the accuracy and implications of clinical nodal positivity.
Methods: Patients ≥ 18 years old with cT1-T2, cN0-cN1, M0 breast cancer were identified in the National Cancer Database between 2004 and 2019.
Comparison of clinical characteristics between ACOSOG Z0011-eligible cohort and sentinel lymph node-positive breast cancer patients in Hong Kong.
Hong Kong Med J
April 2024
Department of Surgery, Queen Mary Hospital, Hong Kong SAR, China.
Introduction: The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial resulted in de-escalation of axillary surgery among early-stage breast cancer patients with low-volume sentinel lymph node (SLN) disease undergoing breast-conserving surgery and radiation therapy. Nevertheless, the mastectomy rate in the Chinese population remains high. This study compared the clinical characteristics of the ACOSOG Z0011-eligible cohort with SLN-positive breast cancer patients in Hong Kong.
View Article and Find Full Text PDFPredicting three or more metastatic nodes using contrast-enhanced lymphatic US findings in early breast cancer.
Insights Imaging
March 2024
Department of Ultrasound, Peking Union Medical College, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.
Article Synopsis
- A nomogram was created to predict patients with early breast cancer who are likely to have three or more metastatic axillary lymph nodes (ALNs) using clinicopathologic data and lymphatic ultrasound findings.
- The study included two cohorts, one for developing the nomogram and another for external validation, with specific ultrasound characteristics linked to a higher likelihood of having ≥ 3 metastatic ALNs.
- The nomogram demonstrated high accuracy with an area under the curve (AUC) of 0.88 and could be a useful tool for guiding treatment decisions in breast cancer management.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!